NATiAS Inc.
Creating paradigm shift in oligonucleotide synthesis and accelerate the innovation of its therapeutics.
Creating paradigm shift in oligonucleotide synthesis and accelerate the innovation of its therapeutics.
NATiAS Inc. is a Japan-based startup that aims to revolutionize oligonucleotide synthesis and accelerate the innovation of therapeutics. The company's unique Blockmer-based technology enables the production of high-purity oligonucleotides in a wide range of scales, from milligrams to tons, at competitive prices. NATiAS Inc. offers various services including oligonucleotide synthesis, Blockmer™ intermediates sales, nucleotide analog synthesis, and mRNA production solutions. Founded in 2015, the company operates in the pharmaceutical industry and has captured the attention of investors. In its latest funding round in October 2020, NATiAS Inc. secured investment from Toray Engineering, emphasizing the recognition and support the startup has received from corporate investors. This investment is a testament to the potential and value that NATiAS Inc. brings to the industry, particularly in the field of oligonucleotide synthesis and therapeutic innovation.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | Unknown | 1 | Toray Engineering | 05 Oct 2020 |
No recent news or press coverage available for NATiAS Inc..
We care about your data, and we'd love to use cookies make your experience better.
